A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

NCT02726386 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: ND0612

Sponsor

NeuroDerm Ltd.